Close X
Get more out of
by joining the site for free
Free 17-point plan to great health
Twice weekly e-news bulletins
Access to our News, Forums and Blogs
Sign up for free and claim your
17-point plan to great health
Free 17-point plan to great health

Twice weekly e-news bulletins

Access to our News, Forums and Blogs

If you want to read our in-depth research articles or
have our amazing magazine delivered to your home
each month, then you have to pay.

Click here if you're interested
Helping you make better health choices

What Doctors Don't Tell You

In shops now or delivered to your home from only £3.50 an issue!

November 2018 (Vol. 3 Issue 9)

Diabetes drug may soon be pulled



Bryan Hubbard is Publisher and co-editor of WDDTY. He is a former Financial Times journalist. He is a Philosophy graduate of London University. Bryan is also the author of several books, including The Untrue Story of You and Secrets of the Drugs Industry.


Diet, cheese, fat, full-fat diet














Diabetes drug may soon be pulled

May 22nd 2007, 15:39

Avandia (rosiglitazone), the diabetes drug, may soon be pulled from markets around the world after a study discovered it increased the risk of heart attack by 45 per cent. America's drug regulator, the Food and Drug Administration (FDA), has issued an urgent safety alert, and is likely to follow up with a complete ban shortly.

Rosiglitazone is in a new family of drugs known as thiazolidinediones that lower blood glucose levels in people with type II diabetes. Another, Muraglitazar, never made it onto the market after it was also found to increase the risk of heart attacks.

As a result, development on a whole generation of thiazolidinediones was abandoned after they were found to be toxic in early-stage trials.

The only other thiazolidinedione that's still on the market is Pioglitazone, and the researchers who have uncovered safety issues about Avandia claim that it is far safer.

The new study, published online by the New England Journal of Medicine on May 21, examined 42 trials, and concluded that the drug increased the risk of heart attack by nearly 45 per cent and, of those, 64 per cent were likely to die from the attack.

The results are very bad news for the manufacturer, GlaxoSmithKline (GSK), whose shares tumbled by 8 per cent in the major markets. The drug is GSK's second biggest seller, with first quarter sales up 19 per cent to lb414m. It's reckoned that millions of people around the world take Avandia.

Other Bloggers discussing this:

Latest Tweet


Since 1989, WDDTY has provided thousands of resources on how to beat asthma, arthritis, depression and many other chronic conditions..

Start by looking in our fully searchable database, active and friendly community forums and the latest health news.

Positive SSL Wildcard

Facebook Twitter

© 2010 - 2018 WDDTY Publishing Ltd.
All Rights Reserved